Navigation Links
Antibiotic Shows Promise as Stroke Treatment
Date:10/1/2007

Minocycline improves patient outcomes if given with 24 hours, study finds

MONDAY, Oct. 1 (HealthDay News) -- An antibiotic used to treat severe acne and urinary tract infections also appears to be a potent weapon against acute ischemic stroke, a new report from Israeli researchers suggests.

Perhaps the best news about this discovery is that it widens the window of treatment for stroke from a few hours to 24 hours, experts say.

Though it is too early to change patient care, should the results be confirmed in larger, placebo-controlled, double-blinded clinical trials, "it will be probably one of the most used and effective treatments of ischemic stroke that we have," said Dr. Argye Hillis, a professor of neurology at the Johns Hopkins University School of Medicine in Baltimore.

The drug in question is minocycline, a tetracycline derivative that has been used for years to fight bacterial infections. Over the past decade, the drug has also been shown to be effective in animal models of several neurological conditions, including Parkinson's, Huntington's and Lou Gehrig's diseases.

Dr. Yair Lampl, of Tel Aviv University, and his colleagues randomized 152 patients with acute ischemic stroke into two groups, one of which received 200 milligrams of minocycline a day for five days, while the other was given a placebo. Treatment was initiated between six and 24 hours after stroke onset.

At one week, one month and three months following stroke, patient recovery was significantly improved in the antibiotic group relative to the control group on each of three tests that collectively assess neurological damage due to stroke and the patient's ability to perform daily tasks such as grooming, dressing and going to the bathroom.

"Statistically, there's a pretty marked difference between the groups," said Dr. Eric Smith, associate director of Acute Stroke Services at Massachusetts General Hospital in Boston. "Clinically, it is the difference between someone who looks almost normal compared to someone with more mild-to-moderate impairment due to stroke."

The findings were published in the Oct. 2 issue of Neurology.

This study focused specifically on ischemic stroke, the kind that is induced by clots that cut off blood flow to parts of the brain. According to Smith, minocycline appears to act as a neuroprotectant -- that is, as a compound that protects the brain from the resulting lack of oxygen and glucose, thereby allowing more brain tissue to survive.

Yet it is not at all clear just how minocycline does this, though several possible mechanisms have been proposed. Lampl suggested the effect "is at least partially dependent" on minocycline's ability to limit inflammation and apoptosis, or cell suicide.

Hillis said she found the results "potentially very exciting," both because of the magnitude of the effect, and because it was observed with a treatment that could be administered as much as a day after a stroke attack.

"They included patients who were eight to 24 hours after onset of stroke, on average 12 hours," she noted. "That's exciting, because that's about when most patients come to the hospital."

Most stroke treatments are now only effective within a few hours of stroke onset, Hillis explained. It's a therapeutic window that is too short to be effective for many patients.

Yet Hillis said she was not yet prepared to change the way she treats her own patients.

"I think this is very promising, very exciting, as a pilot study, but it's not enough to start treating people with minocycline," she said.

Smith concurred, saying, "I think this looks like a promising treatment with pretty big differences in outcome between the minocycline-treated and control groups. However, it is an early-phase study, and the results have to be considered preliminary. The field needs a larger, double-blinded study to confirm these findings."

In a double-blinded study, neither the treating physician nor the patient would be aware which treatment the patient was receiving.

According to Lampl, a larger study is being planned to address this concern.

More information

For more information on minocycline, visit MedlinePlus.



SOURCES: Yair Lampl, M.D., Department of Neurology, Edith Wolfson Medical Center, Holon, Israel; Eric Smith, M.D., M.P.H., FRCPC, assistant professor, neurology, and associate director, Acute Stroke Services, Massachusetts General Hospital and Harvard Medical School, both in Boston; Argye Hillis, M.D., professor, neurology, Johns Hopkins University School of Medicine, Baltimore; Oct. 2, 2007, Neurology


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
2. Antibiotics Helps Autism
3. New antibiotic already developing resistance
4. Antibiotics losing their power against acne
5. Antibiotic induces liver damage in children with E.COLI infections.
6. Vaccine Reduces antibiotic-resistant infections in Children
7. Antibiotic from crab blood indentified
8. Gene clue to antibiotics
9. Excessive use of antibiotics for sore throat
10. E. coli strains resistant to a common antibiotic
11. Cost-effective antibiotics for sinusitis treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business ... Awards . The annual awards, now in their 12th year, are among the most ... winners. , In 2016, the awards were retooled to recognize achievements in both large ...
(Date:3/24/2017)... Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... new clinic which can be found at 9618 Huebner Road. The clinic is the ... PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter ... demand for the product – with nearly 2,000 consumers (and counting) already backing ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: